European Cancer Congress | Conference

Pooled Analysis Reinforces Long-Term Survival Benefit With Ipilimumab

October 2nd 2013

Results from a pooled analysis of data from 12 studies has demonstrated a long-term survival benefit that extends through at least 10 years for patients with advanced melanoma treated with ipilimumab.

Dr. CrinÃ² on Crizotinib in ALK-Positive NSCLC

October 1st 2013

Lucio CrinÃ², MD, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer

Additional OS and PFS Benefits Seen With Aflibercept in Post-Hoc VELOUR Analysis

October 1st 2013

A post-hoc analysis of the VELOUR trial demonstrated additional improvements in both overall survival and progression-free survival in favor of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer

Dr. Hudis on BOLERO-3 Trial Biomarker Observations

October 1st 2013

Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, attending physician, Memorial Sloan-Kettering Cancer Center, comments on exploratory biomarker observations from the BOLERO-3 trial.

Dual HER2 Blockade Less Effective in PI3KCA-Mutant Breast Cancer

October 1st 2013

Breast cancer patients with PI3KCA mutations are less likely to achieve a pathological complete response from dual HER2 blockade in the neoadjuvant setting.

Enzalutamide Plus Abiraterone May Have Higher Response Rate in mCRPC Than Either Agent Alone

October 1st 2013

Co-targeting metastatic castrate resistant prostate cancer with the combination of enzalutamide plus abiraterone acetate may circumvent the compensatory mechanisms observed with either agent alone and lead to more profound suppression of androgen signaling.

Dr. GrÃ¼nwald on Dovitinib Versus Sorafenib in mRCC

September 30th 2013

Viktor GrÃ¼nwald, MD, PhD, from the Hannover Medical School, discusses a phase III trial that compared dovitinib to sorafenib for patients with mRCC following prior treatment with one VEGF inhibitor and one mTOR inhibitor.

Dr. Camidge on a Phase I Study With AZD9291 in NSCLC

September 30th 2013

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses a phase I study looking at AZD9291 in patients with non-small cell lung cancer.

Novel ALK Inhibitor Shows Promise Against Brain Metastasis in NSCLC

September 30th 2013

The first-in-human phase I/II dose-finding study of a novel ALK/EGFR inhibitor called AP26113 demonstrated promising results in both crizotinib-resistant and crizotinib-naÃ¯ve patients with non-small cell lung cancer.

Survival Benefit Observed With Cetuximab in RAS Wild-Type Colorectal Cancer

September 30th 2013

Cetuximab plus FOLFIRI may offer a survival advantage over FOLFIRI plus bevacizumab in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer who do not have RAS mutations.

Dr. George on Critical Clinical Trials in Kidney Cancer

September 30th 2013

Daniel J. George, MD, Director, GU Oncology, Duke Cancer Institute, discusses critical phase III clinical trials in metastatic renal cell carcinoma.

BOLERO-3 Biomarker Study Provides Clues for Response to Everolimus

September 30th 2013

Exploratory analysis of biomarkers in the BOLERO-3 trial suggests that the addition of everolimus to trastuzumab plus vinorelbine for HER2-positive advanced breast cancer may be most beneficial in patients with low PTEN or high pS6 levels.

OS Comparable for Panitumumab and Cetuximab in KRAS Wild-Type mCRC

September 29th 2013

Panitumumab proved noninferior to cetuximab in extending overall survival in patients with chemorefractory KRAS wild-type metastatic colorectal cancer.

PD-L1 Inhibitor Delivers Rapid, Durable Responses in Advanced NSCLC

September 29th 2013

A phase I study has shown remarkable and durable responses with the engineered monoclonal antibody MPDL3280A in metastatic non-small cell lung cancer, including tumors with squamous and adenocarcinoma histology.

T-DM1 Extends PFS in Heavily Pretreated Advanced Breast Cancer

September 29th 2013

T-DM1 extended progression-free survival compared with "physician's choice of treatment" in women with metastatic HER2-positive breast cancer.